Article Text

Download PDFPDF

2022-RA-778-ESGO Rare gynecological cancers in a gynecologic cancer center: 11-year experience of KEM
  1. Malak Moubarak1,
  2. Beyhan Ataseven1,2,
  3. Florian Heitz1,3,
  4. Julia Welz1,
  5. Burcu Baran1,
  6. Nina Pauly1,
  7. Sabrina Kaiser1,
  8. Timo Westermann1,
  9. Alexander Traut1,
  10. Andreas du Bois1 and
  11. Philipp Harter1
  1. 1Gynecology and Gynecologic Oncology, Evangelische Klinken Essen-Mitte, Essen, Germany
  2. 2Department of Obstetrics and Gynecology, University Hospital LMU Munich, Munich, Germany
  3. 3Department for Gynecology with the Center for Oncologic Surgery, Charité Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany


Introduction/Background Many gynecologic cancers fulfill the criteria of a rare tumor with an annual incidence of <6 per 100,000 women. As these tumor entities are difficult to treat, specialized knowledge and skills are necessary. We analyzed the 11-year experience with rare tumors in a tertiary gynecologic oncology center.

Methodology All consecutive patients with rare gynecological cancers treated at our department between 2011 and 2021 were included.

Results 1,460 patients with a rare gynecologic cancer entered our department. 1,092 patients received any kind of therapy and 368 ‘only’ had a consultation. The most common histologic types were: borderline tumors of the ovary (424 pts, 29%), low grade serous ovarian cancer (179 pts, 12.3%), ovarian sex cord-stromal tumors (164 pts, 11.2%), uterine sarcoma (142 pts, 10%), clear cell ovarian cancer (115 pts, 8%), and ovarian germ cell tumors (73 pts, 5%). There was a continuous increase of pts over the years: 237 (2011–2013), 215 (2014–2015), 276 (2016–2017), 347 (2018–2019), 385 (2020–2021) cases. In total, 905 pts came from NRW and 555 patients from other states.

Conclusion We observe a centralization of patients from whole Germany with rare gynecological cancers in our center with a rising number of patients during the observation period. This provides a unique chance for further research in rare gynecologic tumors and also allows to offer prospective trials.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.